Net Loss of Oxygenta Pharmaceutical reported to Rs 2.85 crore in the quarter ended September 2024 as against net loss of Rs 3.16 crore during the previous quarter ended September 2023. Sales rose 7.11% to Rs 14.01 crore in the quarter ended September 2024 as against Rs 13.08 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales14.0113.08 7 OPM %-15.49-15.14 - PBDT-2.11-2.32 9 PBT-2.77-3.15 12 NP-2.85-3.16 10 Powered by Capital Market - Live News

Oxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live News

Oxygenta Pharmaceutical announced that the 31th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live News

Net Loss of Oxygenta Pharmaceutical reported to Rs 1.36 crore in the quarter ended June 2024 as against net loss of Rs 4.56 crore during the previous quarter ended June 2023. Sales rose 83.97% to Rs 12.62 crore in the quarter ended June 2024 as against Rs 6.86 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales12.626.86 84 OPM %-14.03-53.06 - PBDT-2.16-3.93 45 PBT-2.81-4.43 37 NP-1.36-4.56 70 Powered by Capital Market - Live News

Oxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live News